Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Public ClinicalTrials.gov record NCT05778071. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
Study identification
- NCT ID
- NCT05778071
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 165 participants
Conditions and interventions
Interventions
- Placebo Combination Product
- eneboparatide Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 6, 2023
- Primary completion
- Nov 14, 2024
- Completion
- Jun 15, 2027
- Last update posted
- Sep 28, 2025
2023 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Harbor UCLA Medical Center Endocrinology | Torrance | California | 90502 | — |
| Denver Endocrinology Diabetes and Thyroid Center | Denver | Colorado | 80113 | — |
| University of Chicago - Medical Center | Chicago | Illinois | 60637 | — |
| North Shore University Health System | Evanston | Illinois | 60201 | — |
| Indiana University (IU) Health University Hospital | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Northern Nevada Endocrinology | Reno | Nevada | 89511 | — |
| Colombia University Irving Medical Center | New York | New York | 10032 | — |
| Physician's East Endocrinology | Greenville | North Carolina | 27834 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| The Children's Hospital of Philadelphia (CHOP) | Philadelphia | Pennsylvania | 19104 | — |
| The Children's Hospital of Philadephia | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Academy of Diabetes, Thyroid and Endocrine | El Paso | Texas | 79935 | — |
| Arthritis Northwest, PLLC | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05778071, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05778071 live on ClinicalTrials.gov.